Detail akcie Regentis Bio Rg online

Business Summary: Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Regentis Biomaterials Ltd revenues was not reported. Net loss totaled $3.2M vs. income of $7.2M. Net loss reflects Horizon 2020 grant decrease from $2.3M (income) to $0K, Financial Expense - Total increase from $8K to $209K (expense), Research and development expenses increase of 32% to $180K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $1.39 to -$0.62.